Results 121 to 130 of about 526 (152)
Sleep Medicine, 2020 Objective: Solriamfetol (formerly JZP-110), a dopamine/norepinephrine reuptake inhibitor, is approved in the US to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy (75–150 mg/d) or obstructive sleep apnea (37.5 ...
Hélène A Emsellem +2 more
exaly +3 more sources
Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea [PDF]
Sleep, 2020 STUDY OBJECTIVES: To evaluate long-term safety and maintenance of efficacy of solriamfetol treatment for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea (OSA).
Atul Malhotra +2 more
exaly +2 more sources
Human Psychopharmacology, 2022 Objective: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA).
Frederick Vinckenbosch +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Solriamfetol for the Management of Excessive Daytime Sleepiness
Journal of Pharmacy Practice, 2021Objective: To review efficacy, safety, and place in therapy of solriamfetol for management of excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea (OSA). Methods: PubMed (1966 to January 2021) was ...
Megan C Cuomo +2 more
openaire +2 more sources
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial [PDF]
American Journal of Respiratory and Critical Care Medicine, 2019 Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence.
Paula K Schweitzer +2 more
exaly +3 more sources
Behandlung einer symptomatischen Hypersomnie mit Solriamfetol
Nervenheilkunde, 2021ZUSAMMENFASSUNGEs wird der Fall eines 34 Jahre alten Patienten berichtet, der nach einer Epstein-Barr-Virus-Infektion eine symptomatische Hypersomnie entwickelt hat. Diese Hypersomnie konnte mit konventionellen Substanzen nicht befriedigend gebessert werden. Unter Solriamfetol kam es zu einer signifikanten Besserung der exzessiven Tagesschläfrigkeit.
Susan Wald, Stefan Evers
openaire +1 more source
Solriamfetol: First Global Approval
Drugs, 2019Solriamfetol (Sunosi™) is an orally active, selective dopamine and norepinephrine reuptake inhibitor that was recently approved in the USA as a treatment for excessive daytime sleepiness (hypersomnia) associated with narcolepsy and obstructive sleep apnoea (OSA).
openaire +2 more sources
Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion
CNS Spectrums, 2023AbstractIntroductionSolriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The wake-promoting mechanism of solriamfetol may result from dopamine and norepinephrine reuptake inhibition.
Hema Gursahani +7 more
openaire +1 more source
Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults
The Journal of Clinical Psychiatry, 2023Objective: Some individuals with attention-deficit/hyperactivity disorder (ADHD) may not tolerate or adequately respond to currently available treatments. This study examined whether solriamfetol could have a favorable pattern of effects and tolerability as a treatment for ADHD in adults.Methods: Sixty adults with DSM-5 ADHD participated from August ...
Craig B H, Surman +5 more
openaire +2 more sources